… We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage
II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and …

… In this mature update of the European MCL Network trial for older patients, we confirm the
initial results as far as PFS and OS are concerned after R-CHOP induction followed by long-…

… most promising results, this treatment is too toxic for older patients. Several lower-intensity …
in older patients with reduced toxicity profiles. However, older relapsed/refractory patients …

… the older patients with risk variables, frontline treatment is determined according to different
body status of fit, unfit or compromised, and frail. In the fit patients… compromised older patients…

… Treatment of elderly patients with a mantle cell lymphoma (MCL) is a challenge. High-dose …
of the treatment in younger patients, are not feasible for most elderly patients. However, in fit …

… Treatment options for mantle cell lymphomas have expanded considerably over recent …
solutions for older patients with an appropriate risk-to-benefit ratio. Indeed, unfit older patients are …

… often have medical comorbidities that preclude such intensive therapy. Fortunately, an …
patient population. In this article, we will review the current treatment landscape for older adults …

Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma characterized by
t (11; 14)(… 1 With a median age of 65 years, MCL affects predominantly older patients with …

… About 6% of all B-cell non-Hodgkin lymphoma (NHL) patients demonstrate the subtype
mantle cell lymphoma (MCL) (1), with most of these being older people: the median age at …

… of patients with mantle cell lymphoma is expected. Participation in well-designed clinical trials,
also by elderly patients… information on the tolerability of these treatments in this age group. …